Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A. Aftimos P, et al. Among authors: jungels c. Eur J Cancer. 2016 Jun;60:117-24. doi: 10.1016/j.ejca.2016.03.010. Epub 2016 Apr 20. Eur J Cancer. 2016. PMID: 27107326 Clinical Trial.
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours.
Martin-Liberal J, Hollebecque A, Aftimos P, Jungels C, Martin-Romano P, Rodon J, Kremer JD, Zhang W, Bendell J. Martin-Liberal J, et al. Among authors: jungels c. Br J Cancer. 2020 Oct;123(8):1235-1243. doi: 10.1038/s41416-020-1011-7. Epub 2020 Aug 3. Br J Cancer. 2020. PMID: 32741971 Free PMC article. Clinical Trial.
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.
Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjørnsson B, Rekdal Ø. Spicer J, et al. Among authors: jungels c. Clin Cancer Res. 2021 May 15;27(10):2755-2763. doi: 10.1158/1078-0432.CCR-20-3435. Epub 2021 Feb 4. Clin Cancer Res. 2021. PMID: 33542073 Clinical Trial.
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.
Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A. Robbrecht D, et al. Among authors: jungels c. Br J Cancer. 2022 Apr;126(7):1010-1017. doi: 10.1038/s41416-021-01657-7. Epub 2021 Dec 13. Br J Cancer. 2022. PMID: 34903842 Free PMC article. Clinical Trial.
Primary extrarenal rhabdoid tumour of the liver: a case report and literature review.
Meyers Michel, Demetter Pieter, De Roo An-Katrien, Pezzullo Martina, Jungels Christiane, Brichard Bénédicte, De Magnee Catherine, De Krijger Ronald R, Verset Gontran. Meyers Michel, et al. Among authors: jungels christiane. Acta Gastroenterol Belg. 2023 Oct-Dec;86(4):555-562. doi: 10.51821/86.4.11504. Acta Gastroenterol Belg. 2023. PMID: 38240550 Free article. Review.
Editorial: Endocrine tumors, rare tumors.
Jungels C. Jungels C. Curr Opin Oncol. 2021 Jan;33(1):1-2. doi: 10.1097/CCO.0000000000000690. Curr Opin Oncol. 2021. PMID: 33273300 No abstract available.
36 results